Table 2.
Efficacy
| Panobinostat (N = 21) % (95% CI) | Panobinostat + rituximab (N = 19) % (95% CI) | Overall (N = 40) % (95% CI) | ||||
|---|---|---|---|---|---|---|
| Best response category | ||||||
| Overall response CR+PR | 6 | 29 (11.3%-52.2%) | 5 | 26 (9.2%-51.2%) | 11 | 28 (14.6%-43.9%) |
| CR | 5 | 24 | 2 | 11 | 7 | 18 |
| PR | 1 | 5 | 3 | 16 | 4 | 10 |
| SD* | 0 | 0 | 1 | 5 | 1 | 3 |
| PD | 15 | 71 | 13 | 68 | 28 | 70 |
| Time to response, days | ||||||
| All responders | ||||||
| Median | 73 | 21 | 42 | |||
| Range | 23-209 | 21-231 | 21-231 | |||
| CR | ||||||
| Median | 79 | 82 | 79 | |||
| Range | 23-209 | 21-142 | 21-209 | |||
| Duration of response, months | ||||||
| All responders | ||||||
| Median (95% CI) | Not reached | 9.4 (4.3-not reached) | 14.5 (9.4-not reached) | |||
| Range | 6.2-43.2+ | 1.6-40.5+ | 1.6-43.2+ | |||
| Number progressed | 2 | 3 | 5 | |||
*
SD, defined as no criteria for PR or PD for at least 6 months.